downgrad equal-weight
less upsid revenu need reinvest qualiti
support capac may put lrp margin target risk
combin account overhang may take time
manag establish momentum resolut
account issu may drive short-term recoveri share
thesi risk downgrad equal-weight upgrad baxter see
nearli year ago view re-acceler like medic
deliveri stabil signific leverag opportun remain balanc sheet
deploy provid option re-acceler occur may continu
margin reflect view see less
opportun upsid bigger shift rel thesi
reinvest increas qualiti spend may put lrp margin
target risk expect exist account investig
broaden meaning combin spend dynam see
overhang share although note account resolut could
drive short-term recoveri recent under-perform valuat provid
downsid support number like move lower see
prolong path manag re-establish momentum investor
reinvest necessari accounting-driven restat domin
debat discuss lost shuffl realiti baxter may need
reinvest believ could put lrp risk invest
relat renal support aakhi initi see may
understood street capital-expenditure invest qualiti could
surpris downsid challeng clari opelika infer qualiti
remedi alreadi focu baxter two dynam like
factor consensu model
maintain suppli critic baxter taken signific share iv
fluid busi last month concert gpo idn
penetr combin easier compar growth
rebound custom dilig
suggest key element captur extent better price
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
specif contractu assur around maintain consist
suppli agreement place critic suppli met
rais bar requisit infrastructur qualiti invest
 longer lever investor overlook key sourc
leverag repeat compress bp
gener absolut spend back
innov ration program beyond
reduct ill-advis could impact downstream
growth like capital-expenditure invest associ
initi may impair certain extent
see factor put pressur ebit margin well
lower ebit margin assumpt rel
lrp ep estim
street low end lrp
restat like remain line continu believ
account review resolv prior guidanc provid see
insid account background resolut may drive short term
recoveri share evid issu extend beyond
foreign exchang appoint interim treasur may suggest
materi widen scope less like recent pension transact
smaller hedg gain could suppress forward earn rel prior year
previous lower earn see part account
impact downgrad link updat view around issu
acceler thesi aliv well acceler post fluid disrupt
key compon thesi pace acceler may less
signific hope manag provid limit color
assumpt stem model channel dilig analysi
suggest baxter deliv organ growth next year possibl
upsid impli initi guidanc could rel
street chang model reflect
lower pharmaceut outlook myxredlin
momentum like off-set supran dexm brevi cyclo albeit
moder headwind expect lower organ growth
advanc surgeri mse organ growth given lower
floseal growth stem reintroduct surgiflow
renal acut like improv driven primarili eas dialysi
headwind like modest impact etc implement
prismax roll-out meaning move renal estim
adjust acut acut margin bp versu prior estim
deliveri subject great debat commentari
cfo jay saccaro around idn gpo see insid signal chang
price environ materi one view dilig
suggest flat moder declin price consist prior view
estim combin price harder comp drive
deceler line lrp street
lower revenu estim bp
organ growth midpoint growth
would deliv lrp near lower end insid detail
review see outlook segment
downgrad equal-weight see re-acceler
anticip pace fallen short expect underpin prior
overweight thesi importantli leverag gener core
tenet overweight view see visibl cloud pair
account risk lrp may rang bound stock perform
near-term lower price target base ev ebitda
multipl insid med-tech comp sheet
baxter margin ramp faster anticip assum compound-annual-growth-rate
back new product initi margin hit higher expect
guidanc om/gm ratio larg cap devic peer
baxter deploy capit wacc return diversifi
baxter achiev organ sale growth new product
geograph expans drive acceler margin continu expand baxter
execut tuck-in medium size deal also buy back stock
baxter new product initi fail deliv growth slow compound-annual-growth-rate
margin expans effort reliant upon benefit product mix fail
materi margin expans slow materi result oper
margin strateg action fail occur deliv wacc
baxter current multipl reflect
wamgr potenti
acceler medic deliveri
nutrit dynam stabil pipelin
baxter premium balanc sheet asset
risk low-return capit deploy
overst expect disciplin
approach involv repurchas
medic deliveri nutrit
headwind stabil contribut
low mid-singl digit growth
growth leverag opportun allow
baxter reach low-doubl digit earn
growth level
stabil medic deliveri
nutrit drive acceler
baxter expect new product sale
drive pt baxter
deploy balanc sheet
bp margin expans drive
pt earn
roll-out next-gen pump platform launch
risk achiev price
medic deliveri nutrit
recov expect
potenti activ below- wacc
inabl gener oper leverag
baxter struggl grow wamgr
deeper dive outlook
account investig happen next octob baxter
announc begun intern investig misstat previous
report non-oper incom relat fx gain loss visibl process
limit time estim uncertain relat fx
comment natur misstat note misstat
strictli relat translat baxter would like sole see account impact
influenc non-oper incom impact histor cash flow
howev misstat relat settl intra-compani transact
could cash flow implic expect overhang resolv near
term compani would like work avoid let investig impair
abil guid also evid issu extend beyond fx
recent activ appoint interim treasuri cfo market suggest
materi widen scope less like see resolut issu earli
think multipl recov instantan
baxter deliv organ growth next year possibl upsid
initi guidanc could rel street outlook would
deliv lrp near lower end busi like improv
includ renal acut driven primarili etc model implement
prismax roll-out respect lower pharmaceut outlook
myxredlin momentum like off-set supran dexm brevi cyclo
albeit moder headwind expect lower organ growth advanc
surgeri given tougher comp headwind floseal deliveri
subject great debat commentari cfo jay saccaro around final
agreement variou gpo idn hospit product busi
signal materi chang price environ consist
dilig environ gone posit price stabl potenti
neg combin dynam increas suppli harder comp
drive deceler line lrp street
renal could winner esrd treatment choic
etc model expect final implement begin
drive us renal acceler repres slight delay rel
initi januari target see slip beyond april delay
would requir legisl action ex us could slightli bolster continu
kaguya roll-out addit expect theranova medicar add-on reimburs
grant anticip provid uplift revenu
model annual push us renal growth
acut therapi look good year ahead recent prismax launch
potenti solid growth driver low double-digit us growth primarili
given current underpenetr us current versu ou
kick segment high single-digit growth gear
medic deliveri like grow organ primarili result
tougher comp due rebound well price concess
kick note del benefit full year cheetah
contribut add bp growth segment bp
expect pharma acceler primarili back myxredlin
launch bp well moder cyclo brevi headwind bp
collect laid headwind tailwind detail see
nutrit also expect solid deliv organ growth
driven product rollout clinimix high protein us launch
advanc surgeri expect chug along low single-digit organ
growth territori primarili given tougher comp follow boost
suppli constraint episod mid inorgan note assum mid-
year close seprafilm could deliv revenu repres
bp tailwind corporate-level growth analysi
valuat methodolog risk associ recommend rate price target referenc report pleas contact client support follow us/canada hong kong
latin america london singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
st def tax asset disposit
current matur lt debt leas oblig
commit conting
oper
incom disc op net tax
depreci amort
realiz excess tax benefit stock issu employ benefit plan
net period pension benefit opeb cost
sale discontinu oper
infus product-rel charg
loss gain relat conting payment liabil
chang balanc sheet item
oper
invest
acquisit invest net
divestitur invest activ
invest
financ
issuanc debt
payment oblig
increas decreas st debt
dividend common stock
proce realiz excess tax benefit stock issu employe benefit plan
purchas treasuri stock issuanc equiti
financ
effect exchang rate chang
begin period balanc
end period balanc
